Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 9, 2009

Pfizer and Crown Team Up to Develop Treatments for Asian Cancers

  • Pfizer is partnering with oncology services company Crown Bioscience to develop novel therapeutics for cancers prevalent in Asia. The joint research will be carried out at Crown’s new facility near Shanghai and aims to discover and advance multiple candidates for clinical development.

    Crown will receive an upfront payment and research funding under the terms of the deal with Pfizer. It is also eligible to preclinical and development milestones as products progress.

    Based in California, Crown operates wholly owned research facilities at campuses in Beijing and Taicang, China, and in Indianapolis. The company claims its CrystalClear™ and HuPrime™ platforms provide unique capabilities in lead optimization and translational oncology for the development of clinical candidates.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »